Horst G. Zerbe, Ph.D.

Chairman of the Board, President and CEO and founder of IntelGenx. Previously, Dr. Zerbe served as the President of Smartrix Technologies Inc. in Montreal, and as Vice President of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ. Dr. Zerbe holds over 40 patents in drug delivery related fields and has published numerous scientific papers in recognized journals.

J. Bernard Boudreau, QC, PC

has a distinguished record as a lawyer, businessman and public figure. He founded and served as the senior partner of a law firm in Nova Scotia and was appointed Queen’s Counsel in 1985. He was first elected to the provincial legislature of Nova Scotia in 1988, where he served in various senior cabinet positions including Minister of Finance and Minister of Health. In 1999, the Prime Minister of Canada appointed Mr. Boudreau to the positions of Leader of the Government in the Senate of Canada and the Federal Minister responsible for Nova Scotia. The legislative highlight of his career in the Senate came when he led the fight in that Chamber to pass the Clarity Act, working in close cooperation with the Honorable Stéphane Dion and Prime Minister Chrétien. In 2001, he resumed his private career as President and CEO of Radcliffe Consulting and Investment Ltd. in Halifax, Nova Scotia. In March 2001, he was appointed a Director of Export Development Canada (“EDC”), serving as Chairman of the Pension and Human Resource Committees of that Board. He also serves on the Board of Directors of a number of other public and private corporations.

John S. Marinucci, C.A., ICD.D, H.R.C.C.C.

is the former President and Chief Executive Officer of New Flyer Industries Inc. During his seven year tenure with New Flyer, Mr. Marinucci successfully restructured its manufacturing operations and the aftermarket services business transforming New Flyer into the North American leader in the heavy-duty transit market. Under his leadership, New Flyer completed its IPO in August 2005 and successfully completed secondary offerings in July 2007 and April 2008. Previously, he served as President and Chief Operating Officer for National Steel Car and is a former President of the Canadian Association of Railway Suppliers. Mr. Marinucci currently serves on the board of directors for New Flyer, CWB Group, Seaport Intermodal Inc., and Pillar5 Pharma.

Bernd J. Melchers

business economist, is a 30-year veteran of the pharmaceutical and health care industry with extensive experience in corporate financial management. Most recently, he was Managing Director of 3M Dyneon Holding GmbH, Germany and Global Chief Financial Officer of the world wide operating 3M Dyneon Group, a subsidiary of 3M Corporation headquartered in Minnesota. Previously, he served as the European Controller of 3M Medical Markets at the 3M Europe Headquarter located in Brussels, Belgium. Prior to this he held various senior management positions at the Medical-Surgical Division of 3M in St. Paul, Minnesota, at 3M Health Care Products, Germany, and 3M Pharmaceutical Products, Germany.

Clemens Mayr, LLB

has been a partner of McCarthy Tétrault LLP since 2006, a leading Canadian law firm. His practice focusses on M&A and capital markets, both domestic and cross-border. In the course of his practice he has advised corporations and boards in numerous industries, including in particular life-sciences and technology. He currently also serves on the board of partners of McCarthy Tétrault LLP and on the board of directors of the Institute of Corporate Directors (Quebec Chapter). He is also the chair of the Legal Advisory Committee of the AMF (the Québec securities regulatory authority). He received his LLB from the Université de Montreal in 1990 and was called to the Quebec bar in 1991.

Mark Nawacki, CPA, CA, MBA

is currently the President & CEO of Searchlight Pharma Inc., a Canadian-based specialty pharmaceutical company focused on the acquisition and commercialization of innovative and unique healthcare and pharmaceutical products. Prior to joining Searchlight Pharma, Mark spent over 11 years building out the commercial and geographic footprint of Paladin Labs Inc., having served until September 2014 as Executive Vice President, Business and Corporate Development, followed by an independent international consulting mandate with Endo International PLC until February 2015. Mark joined Paladin in September 2003 and held responsibility for all business, corporate and product development activities at Paladin, a leading Canadian specialty pharmaceutical company. During his over 11-year tenure at Paladin, Mark concluded over 80 business development transactions spanning product in and out licensing, all variety of product partnership transactions, product acquisitions, and corporate M&A deals. From his arrival at Paladin in 2003, consolidated revenues grew from about $20 million to almost $270 million annually and Paladin’s share price rose from approximately $5 to a peak of $151 per share at the time of Paladin’s acquisition by Endo Healthcare Solutions. Prior to joining Paladin, Mark held progressively senior leadership positions at Pharmacia, a global top 10 pharmaceutical company that is now part of Pfizer Inc. While at Pharmacia, Mr. Nawacki specialized in the cardiology and pain therapeutic areas, and was responsible for Canadian business development initiatives.

Ian Troup, B.Sc.

has more than 40 years of experience in the pharmaceutical industry, most recently serving as President and Chief Operating Officer of Upsher-Smith Laboratories, a privately held generic pharmaceutical company, prior to which he was President of Schwarz Pharma USA. He is currently an active board member of several Minneapolis-based businesses including: Medisyn Technologies, a privately funded corporation involved in computer based topological drug design and TwinWest PAC, a political action committee helping Minnesota businesses gain local, state and federal access to political officials.

Ingrid Zerbe

Corporate Secretary and co-founder of IntelGenx Corp.